Abstract Purpose: Tissue-of-origin prediction and tumor subtyping enable more precise treatment selection, especially for cancers of unknown primary (CUP) or without a defined subtype, though these remain a challenge in liquid biopsy applications. Current genomic approaches include methylation profiling or whole-genome sequencing, which require additional laboratory workflows on top of comprehensive genomic profiling, or may utilize multiple detected somatic alterations, which may not be present